Navigation Links
Sunesis Pharmaceuticals Receives NASDAQ Notification
Date:4/17/2009

ception to the continued listing requirements on The NASDAQ Global Market and the Company's ability to raise additional funding in the future. Words such as "believes," "intends," "may," "opportunity" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to Sunesis' need for and timing of additional funding, Sunesis' ability to raise additional capital, the risk that the NASDAQ Staff may reject the Company's plan for meeting the minimum continued listing requirements and the Company otherwise fails to comply with the continued listing requirements of The NASDAQ Global Market or any other NASDAQ market. These and other risk factors are discussed under "Risk Factors" and elsewhere in Sunesis' Annual Report on Form 10-K for the year ended December 31, 2008 and other filings with the Securities and Exchange Commission. Sunesis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.

    Investor Contact:                         Media Contact:
    Sunesis Pharmaceuticals, Inc.             Sunesis Pharmaceuticals Inc.
    Eric Bjerkholt                            Dan Weinseimer
    650-266-3717                              650-266-3739


'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
2. Sunesis to Present at the 11th Annual BIO CEO & Investor Conference
3. Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin
4. Sunesis to Present at Upcoming Conferences
5. Sunesis to Present at Upcoming Conferences
6. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
7. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
8. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
9. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
10. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
11. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... NEW YORK , June 30, 2015  Today, Americord ... the U.S., announced Andrew Horne , a partner at ... Advisory Board. Logo - http://photos.prnewswire.com/prnh/20150630/226958LOGO   ... appointment to Americord,s Advisory Board," says Martin Smithmyer , ... experience in his legal career that will assist Americord,s growth ...
(Date:6/30/2015)... ... June 30, 2015 , ... The maximum number of ... currently outstanding common shares (including shares of unvested restricted stock). On June 29, 2015, ... sale price of Cryo-Cell’s shares reported on the OTCBB was $2.29 per share. , ...
(Date:6/30/2015)... VANCOUVER , June 30, 2015 /PRNewswire/ - ... a clinical stage regenerative medicine company focused on ... the first participant in its Phase 1/2 clinical ... of chronic unilateral Achilles tendinosis, has been enrolled ... to intra-tendon ultrasound-guided injections. RCT-01 is comprised of ...
(Date:6/30/2015)... ... 2015 , ... Cannavoices , Inc., a premier legal ... and broadcast initiative. Produced by filmmakers, the multi-platform initiative aims to become not ... stories ever assembled. , Cannavoices profiles Advocates, Patients, Entrepreneurs, Growers, Investors, Ancillary ...
Breaking Biology Technology:Americord Registry Announces Andrew Horne as Advisory Board Member 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3
... N.J., Aug. 6 Millennium,Biotechnologies, Inc., a wholly ... Board: MBTG) today named Mark C.,Mirken its new ... of,Directors., Mirken has been President and Chief ... in September of 2007. Mirken will replace Jerry,Swon ...
... 6 Pressure,BioSciences, Inc. (Nasdaq: PBIO ) ... of its pressure cycling technology ("PCT")-enhanced,trypsin digestion application ... family of products. Named "Proteolysis (Trypsin)-PrEP", this new,PCT-enhanced ... & Development of Innovative Therapeutics Expo 2008, being ...
... Line with Company Estimates Highlighted by 11% Discovery ... Products and Services Growth -, ... CALP ) today reported second quarter financial,results for 2008. Revenues were ... year quarter of $35.3 million. Revenues were impacted,by a $3.5 million ...
Cached Biology Technology:Mark C. Mirken Named New CEO and Chairman of the Board of Millennium Biotechnologies, Inc. 2Mark C. Mirken Named New CEO and Chairman of the Board of Millennium Biotechnologies, Inc. 3Pressure BioSciences, Inc. Announces the Market Release of its PCT-Enhanced Trypsin Digestion Application for Proteomics 2Pressure BioSciences, Inc. Announces the Market Release of its PCT-Enhanced Trypsin Digestion Application for Proteomics 3Pressure BioSciences, Inc. Announces the Market Release of its PCT-Enhanced Trypsin Digestion Application for Proteomics 4Pressure BioSciences, Inc. Announces the Market Release of its PCT-Enhanced Trypsin Digestion Application for Proteomics 5Caliper Life Sciences Reports Second Quarter 2008 Results 2Caliper Life Sciences Reports Second Quarter 2008 Results 3Caliper Life Sciences Reports Second Quarter 2008 Results 4Caliper Life Sciences Reports Second Quarter 2008 Results 5Caliper Life Sciences Reports Second Quarter 2008 Results 6Caliper Life Sciences Reports Second Quarter 2008 Results 7Caliper Life Sciences Reports Second Quarter 2008 Results 8Caliper Life Sciences Reports Second Quarter 2008 Results 9
(Date:6/16/2015)... , June 16, 2015  With the increasing ... security remains a top concern. The recent compromise of ... the need for strong authentication within government agencies. ... a biometric one-time password (OTP) authenticator, has been submitted ... (FIPS) 140-2 Level 3 validation for tamper proofing. ...
(Date:6/15/2015)... -- A new report [ 1 ... US consumers using mobile banking applications want their mobile devices ... voiceprint, instead of having to prove who they are with ... Identity   -   The Fusion of Financial Services, Mobile ... primary channel used by Gen X and Gen Y to ...
(Date:6/10/2015)... June 10, 2015 According ... Market by Technology (Ultrasound, TOF, Structured Light, Stereo ... Entertainment, Automotive) and by Geography - Trends & ... the market is expected to reach $3,319.71 Million ... between 2015 and 2020. Browse 71 ...
Breaking Biology News(10 mins):Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 43D Sensor Market Worth $3,319.71 Million by 2020 23D Sensor Market Worth $3,319.71 Million by 2020 33D Sensor Market Worth $3,319.71 Million by 2020 4
... South Carolina, 7. Dezember 2012 /PRNewswire/ -- Integrated ... FBI-Zertifizierung seiner neuesten Fingerabdrucktechnologie einen weiteren technologischen ... das neue Produkt unter Verwendung der LES-Technologie ... Dünnfilmtransistor (Thin Film Transistor, TFT) her. Die ...
... New Rochelle, NY, December 6, 2012Enzymes play a crucial ... decreasing the energy consumption of biochemical reactions in many ... enhance the biocatalytic activity of an industrial enzyme are ... , a peer-reviewed journal from Mary Ann Liebert, Inc., ...
... and produce offspring of mixed ancestry? Recent genetic ... modern humans tens of thousands of years ago in ... pool. But the findings are not universally accepted, and ... role of interbreeding, which is also known as hybridization. ...
Cached Biology News:Integrated Biometrics stellt Sherlock vor - die weltweit leichtesten, dünnsten und kleinsten Appendix F Mobile ID-Fingerabdrucksensoren 2Can compressed fluids increase enzyme activity in industrial bioprocesses? 2Monkey business: What howler monkeys can tell us about the role of interbreeding in human evolution 2Monkey business: What howler monkeys can tell us about the role of interbreeding in human evolution 3
Purified anti-SOCS3...
Tumor Suppressor Sampler Kit 10 mu g each...
AMAP Multi Site-directed Mutagenesis Kit Research Focus: other Storage Temperature: -20C Shipping Temperature: dry ice...
Umbilical cord blood eosinophils, For immunohistochemistry (IHC)...
Biology Products: